Covid vaccine dry run across India on Jan 2

After successfully concluding the coronavirus vaccination dry run in four states, a similar mega-drill will be conducted in all states and union territories across India on January 2

Jan 01, 2021
Image
A

After successfully concluding the coronavirus vaccination dry run in four states, a similar mega-drill will be conducted in all states and union territories across India on January 2. This is aimed at equipping the entire administration and management of vaccine supply, storage and logistics, including cold chain management, the Health Ministry said on Thursday.

The activity is proposed to be conducted in all state capitals in at least three session sites. Some states will also include districts that are situated in difficult terrain or have poor logistical support.

"The objective of the dry run for COVID-19 vaccine introduction is to assess operational feasibility in the use of Co-WIN application in field environment, to test the linkages between planning and implementation and to identify the challenges and guideway forward prior to actual implementation," the ministry added.

As the vaccine administrators will play an important role in the vaccination process, training of trainers and those who shall administer the vaccine has been taken up across various states. Around 96,000 vaccinators have been trained for this purpose.

After a year which saw an unprecedented global health crisis, many are anticipating the coronavirus vaccine as India prepares for the inoculation campaign, which is likely to commence in January 2021.

The central government plans to vaccinate nearly 300 million people in the first phase of drive. It will be offered to 10 million healthcare workers, along with 20 million frontline and essential workers and 270 million elderly, mostly above the age of 50 years with comorbidities.

India currently has eight Covid-19 vaccine candidates, including three indigenous vaccines, under different stages of clinical trials which could be ready for authorisation in near future. Serum Institute-Oxford's Covishield, Bharat Biotech's Covaxin and Pfizer vaccine are in the fray for emergency use authorisation.

(IANS)

Post a Comment

The content of this field is kept private and will not be shown publicly.